COVID-19 Vaccine Trial Testing Extra Dose in MS, Other Diseases

COVID-19 Vaccine Trial Testing Extra Dose in MS, Other Diseases

304490

COVID-19 Vaccine Trial Testing Extra Dose in MS, Other Diseases

A new clinical trial launched by the National Institutes of Health (NIH) is evaluating the impact of an extra dose of an approved or authorized COVID-19 vaccine in people with multiple sclerosis (MS) and other autoimmune diseases who did not properly respond to an original vaccine regimen. Approximately 600 people will be enrolled in the Phase 2 trial (NCT05000216) — officially called COVID‐19 Booster Vaccine in Autoimmune Disease Non‐Responders. The study is open to people with MS…

You must be logged in to read/download the full post.